BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 712,617 shares of the biopharmaceutical company’s stock after selling 40,260 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned about 0.05% of Gilead Sciences worth $50,439,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of GILD. Bank of New York Mellon Corp grew its stake in Gilead Sciences by 9.8% during the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after purchasing an additional 2,727,063 shares in the last quarter. Parnassus Investments CA grew its stake in Gilead Sciences by 37.4% during the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after purchasing an additional 4,556,901 shares in the last quarter. APG Asset Management N.V. grew its stake in Gilead Sciences by 16.7% during the 1st quarter. APG Asset Management N.V. now owns 5,923,426 shares of the biopharmaceutical company’s stock valued at $402,319,000 after purchasing an additional 849,741 shares in the last quarter. AQR Capital Management LLC grew its stake in Gilead Sciences by 25.7% during the 1st quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock valued at $354,070,000 after purchasing an additional 1,066,172 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. grew its stake in Gilead Sciences by 6.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 4,706,832 shares of the biopharmaceutical company’s stock valued at $333,150,000 after purchasing an additional 302,787 shares in the last quarter. Institutional investors and hedge funds own 73.97% of the company’s stock.

A number of equities research analysts have weighed in on the company. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Thursday, August 31st. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price objective for the company. in a research note on Monday, August 28th. Cowen and Company restated an “outperform” rating and set a $90.00 price objective on shares of Gilead Sciences in a research note on Wednesday, July 5th. Finally, Wells Fargo & Company raised their price objective on Gilead Sciences from $73.00 to $81.00 and gave the company a “market perform” rating in a research note on Wednesday, September 6th. Twelve analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $85.80.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/10/16/british-columbia-investment-management-corp-sells-40260-shares-of-gilead-sciences-inc-gild.html.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 81.17 on Monday. The firm has a 50 day moving average price of $82.48 and a 200-day moving average price of $72.25. The firm has a market cap of $106.00 billion, a PE ratio of 8.82 and a beta of 1.14. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the prior year, the business posted $3.08 EPS. The company’s quarterly revenue was down 8.2% on a year-over-year basis. On average, analysts predict that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. Gilead Sciences’s dividend payout ratio is 22.58%.

In other news, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total transaction of $2,066,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at $242,749,648.34. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 486,819 shares of company stock valued at $39,298,919. Company insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.